Raquel Pérez-Robles

Raquel Pérez-Robles

Auto-generated profile, based on publicly available information

Raquel Pérez-Robles

Inst Invest Biosanit Granada ibs GRANADA, Granada, Spain

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in Chemometrics and Intelligent Laboratory Systems
Verified
Journal Article
Closed access
RPRaquel Pérez-Robles
Raquel Pérez-Robles
NNNatalia Navas
Natalia Navas
SMSantiago Medina-Rodríguez
Santiago Medina-Rodríguez
LCLuis Cuadros-Rodríguez
Luis Cuadros-Rodríguez

18 January 2023 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Open access
RPRaquel Pérez-Robles
Raquel Pérez-Robles
ASAntonio Salmerón-García
Antonio Salmerón-García
JFJesús Hermosilla Fernández
Jesús Hermosilla Fernández
ATAnabel Torrente
Anabel Torrente
SBSusana Clemente Bautista
Susana Clemente Bautista
NNNatalia Navas
Natalia Navas
Teduglutide (Revestive (R)) is a glucagon-like peptide-2 analogue used for the treatment of short bowel syndrome, a rare life-threatening condition in which the amount of functional gut is too short to enable proper absorption of nutrients and fluids. During handling prior to administration to the patient in hospital, it is possible that peptide -based medicines may be exposed to environmental stress conditions that could affect their quality. It is therefore essential to carry out stress testing studies to evaluate how such medicines respond to these stresses. For this reason, in this paper we present a strategy for a comprehensive analytical characterization of a peptide and a stress testing study in which it was subjected to various stress conditions: heating at 40 degrees C and 60 degrees C, light exposure and shaking. Several complementary analytical techniques were used throughout this study: Far UV circular dichroism, intrinsic protein fluorescence spectroscopy, dynamic light scattering, size-exclusion chro-matography and intact and peptide mapping reverse-phase chromatography coupled to mass spectrometry. To the best of our knowledge, this is the first study to offer an in-depth description of the chemical structure of teduglutide peptide and its physicochemical characteristics after stress stimuli were applied to the reconstituted medicine Revestive (R).

10 October 2022 in Analytical Methods
Verified
Journal Article
Open access
PDF file
RPRaquel Pérez-Robles
Raquel Pérez-Robles
ASAntonio Salmerón-García
Antonio Salmerón-García
SCSusana Clemente-Bautista
Susana Clemente-Bautista
IJInés Jiménez-Lozano
Inés Jiménez-Lozano
MCMaría Josep Cabañas-Poy
María Josep Cabañas-Poy
NNNatalia Navas
Natalia Navas
Teduglutide (Revestive®, 10 mg mL−1) is a recombinant human glucagon-like peptide 2 analogue, used in the treatment of short bowel syndrome, a serious and highly disabling condition which results from either too small a length of intestine or loss of critical intestinal function. The determination of therapeutic compounds of protein-nature is always challenging due to their complex structure. In this work, we present a fast, straightforward reversed phase (RP)UHPLC-UV-(HESI/ORBITRAP)MS method for the identification and quantification of the intact teduglutide peptide. The method has been developed and validated in accordance with the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines; therefore, linearity, limits of detection and quantification, accuracy (precision and trueness), robustness, system suitability and specificity using the signal from the UV and MS, have been evaluated. The validation performance parameters obtained from the UV and MS signals were compared throughout the work, to select the most suitable. To study the specificity of the method and the impact of medicine mishandling under hospital conditions, force degradation studies were performed, i.e. thermal (40 °C and 60 °C), shaking (mechanical) and light (accelerated exposition) effects. Identification by the exact mass of teduglutide was achieved and it was confirmed that the peptide does not undergo any post-translational modifications (PTMs). To the best of our knowledge, the present work reports the first method developed for the simultaneous identification, structural characterization, and quantification of the therapeutic teduglutide peptide. Finally, the proposed method is able to indicate stability when quantifying the intact teduglutide since detects and characterises the exact mass of the degradation/modification products.